Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
09 2021
Historique:
received: 26 06 2020
accepted: 20 09 2020
pubmed: 1 10 2020
medline: 30 9 2021
entrez: 30 9 2020
Statut: ppublish

Résumé

Prevention of vaccine-preventable diseases is important in the care of patients with inflammatory bowel disease (IBD). Thus, accurate immunization histories are critical. Many providers rely on patient self-report when assessing immunization status. The primary aim of our study was to determine the accuracy of self-reported influenza vaccination status in a cohort of patients with IBD. We conducted a prospective study of patients with IBD who answered a vaccination status questionnaire and compared their responses to the Wisconsin Immunization Registry, a state-wide electronic immunization information system. The primary outcome was the sensitivity and specificity of self-reported influenza vaccination status. A secondary outcome evaluated the sensitivity and specificity of pneumococcal vaccination status. A total of 200 patients with IBD were included in the study. Documented immunization rates were 74.5% for influenza vaccinations and 79.9% for pneumococcal vaccinations. Influenza vaccination self-report had a sensitivity of 98.7%, a specificity of 90.2%, a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 95.8%. In comparison, the sensitivity for pneumococcal vaccination was 83.5% with a specificity of 86.2%, PPV of 96.4%, and NPV of 54.3%. Self-reported influenza immunization status is sensitive and specific in patients with IBD. Accuracy for pneumococcal vaccination is slightly lower, but responses were notable for a high PPV. Self-report is an effective way to determine influenza immunization status and provides useful information for receipt of pneumococcal vaccine in patients with IBD.

Sections du résumé

BACKGROUND AND AIMS
Prevention of vaccine-preventable diseases is important in the care of patients with inflammatory bowel disease (IBD). Thus, accurate immunization histories are critical. Many providers rely on patient self-report when assessing immunization status. The primary aim of our study was to determine the accuracy of self-reported influenza vaccination status in a cohort of patients with IBD.
METHODS
We conducted a prospective study of patients with IBD who answered a vaccination status questionnaire and compared their responses to the Wisconsin Immunization Registry, a state-wide electronic immunization information system. The primary outcome was the sensitivity and specificity of self-reported influenza vaccination status. A secondary outcome evaluated the sensitivity and specificity of pneumococcal vaccination status.
RESULTS
A total of 200 patients with IBD were included in the study. Documented immunization rates were 74.5% for influenza vaccinations and 79.9% for pneumococcal vaccinations. Influenza vaccination self-report had a sensitivity of 98.7%, a specificity of 90.2%, a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 95.8%. In comparison, the sensitivity for pneumococcal vaccination was 83.5% with a specificity of 86.2%, PPV of 96.4%, and NPV of 54.3%.
CONCLUSIONS
Self-reported influenza immunization status is sensitive and specific in patients with IBD. Accuracy for pneumococcal vaccination is slightly lower, but responses were notable for a high PPV. Self-report is an effective way to determine influenza immunization status and provides useful information for receipt of pneumococcal vaccine in patients with IBD.

Identifiants

pubmed: 32995995
doi: 10.1007/s10620-020-06631-6
pii: 10.1007/s10620-020-06631-6
pmc: PMC7524037
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2935-2941

Informations de copyright

© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn’s disease in adults. Am J Gastroenterol.. 2018;113:481–517.
pubmed: 29610508
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol.. 2019;114:384–413.
pubmed: 30840605
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology.. 2019;156:769–808.e29.
pubmed: 30576642
Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1465–96.e17.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol.. 2013;108:240–248.
pubmed: 23295276 pmcid: 4624299
Vinsard DG, Wakefield D, Vaziri H, Karagozian R. Vaccine-preventable diseases in hospitalized patients with inflammatory bowel disease: A nationwide cohort analysis. Inflamm Bowel Dis.. 2019;25:1966–1973.
pubmed: 31067308
Tinsley A, Navabi S, Williams ED, et al. Erratum to increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis.. 2019;25:369–376.
pubmed: 30020478
Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: A nationwide danish cohort study 1977-2013. Am J Gastroenterol.. 2015;110:1582–1587.
pubmed: 26346865
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther.. 2013;37:420–429.
pubmed: 23240738
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: More than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol.. 2012;107:1409–1422.
pubmed: 22890223 pmcid: 3438468
Launay O, Abitbol V, Krivine A, et al. Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: A two-year prospective study. J Crohns Colitis.. 2015;9:1096–1107.
pubmed: 26351392
Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: A nationwide cohort study. Clin Gastroenterol Hepatol.. 2018;16:1919–27.e3.
Chang K, Lee HS, Kim YJ, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clin Gastroenterol Hepatol.. 2018;16:1928–36.e2.
Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: Preventive care in inflammatory bowel disease. Am J Gastroenterol.. 2017;112:241–258.
pubmed: 28071656
Pham HV, Hasan I, Udaltsova N, et al. Rates and predictors of vaccinations among inflammatory bowel disease patients receiving anti-tumor necrosis factor agents. Dig Dis Sci.. 2018;63:209–217.
pubmed: 28836068
Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis.. 2008;14:253–258.
pubmed: 17932966
Xu F, Dahlhamer JM, Terlizzi EP, Wheaton AG, Croft JB. Receipt of preventive care services among US adults with inflammatory bowel disease, 2015–2016. Dig Dis Sci.. 2019;64:1798–1808.
pubmed: 30746631
Boltin D, Gingold-Belfer R, Kimchi NA, Ben-Bassat O, Niv Y, Birkenfeld S. Utilization of influenza immunization in adults with Crohn’s disease—a longitudinal, population-based study. Inflamm Bowel Dis.. 2014;20:240–245.
pubmed: 24374880
Caldera F, Saha S, Wald A, et al. Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home. Expert Rev Gastroenterol Hepatol.. 2016;10:759–766.
pubmed: 27029237 pmcid: 4970643
Freedman M, Kroger A, Hunter P, Ault KA. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med.. 2020;172:337–347.
pubmed: 32016359
Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol.. 1992;136:296–307.
pubmed: 1415151
Schoenborn CA, Heyman KM. Health characteristics of adults aged 55 years and over: United States, 2004–2007. Natl Health Stat Report.. 2009;16:1–31.
Mac Donald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med.. 1999;16:173–177.
pubmed: 10198654
Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine.. 2003;21:1486–1491.
pubmed: 12615445
Mangtani P, Shah A, Roberts JA. Validation of influenza and pneumococcal vaccine status in adults based on self-report. Epidemiol Infect.. 2007;135:139–143.
pubmed: 16740194
Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Dig Liver Dis.. 2018;50:563–567.
pubmed: 29371056
Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: Attitudes, knowledge, and uptake. J Crohns Colitis.. 2015;9:439–444.
pubmed: 25908717
Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y).. 2015;11:396–401.
Wisconsin Department of Health Services. Wisconsin Immunization Registry (WIR) 2000 [Available from: https://www.dhs.wisconsin.gov/immunization/wir.htm . Accessed May 1, 2019.
Centers for Disease Control and Prevention. Immunization Information System: Centers for Disease Control and Prevention; [Available from: https://www.cdc.gov/vaccines/programs/iis/annual-report-iisar/2018-data.html#adult . Accessed May 1, 2019.
Koepke R, Petit AB, Ayele RA, et al. Completeness and accuracy of the wisconsin immunization registry: An evaluation coinciding with the beginning of meaningful use. J Public Health Manag Pract.. 2015;21:273–281.
pubmed: 25590511
Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine.. 2009;27:6546–6549.
pubmed: 19729083
Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors? Vaccine.. 2013;31:3928–3935.
pubmed: 23806243 pmcid: 4689428
Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: Results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis.. 2017;64:829–838.
pubmed: 28362949
Matsumoto H, Ohfuji S, Watanabe K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: A randomized controlled trial. J Gastroenterol.. 2015;50:876–886.
pubmed: 25672513
Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. Jama.. 1999;281:243–248.
pubmed: 9918479
Poland GA. The prevention of pneumococcal disease by vaccines: Promises and challenges. Infect Dis Clin North Am.. 2001;15:97–122.
pubmed: 11301826
Reich JM, Canakis AD, Shankar DM, Harrington JM, Apte MM, Weinberg JS, et al. The use of An EHR patient portal (Mychart-Epic) in patients with inflammatory bowel disease. Crohn’s and Colitis 3602019.
Szilagyi PG, Albertin C, Casillas A, Valderrama R, Duru OK, Ong MK, et al. Effect of patient portal reminders sent by a health care system on influenza vaccination rates: A randomized clinical trial. JAMA Intern Med. Epub. Published online May 18, 2020.
Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci.. 2011;56:819–824.
pubmed: 20668942
Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis.. 2011;17:2536–2540.
pubmed: 21538710
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis.. 2014;58:309–318.
pubmed: 24421306
Srivastav A, Black CL, Lutz CS, Fiebelkorn AP, Ball SW, Devlin R, et al. U.S. clinicians’ and pharmacists’ reported barriers to implementation of the Standards for Adult Immunization Practice. Vaccine. 2018;36:6772–81.
Vaccination Programs: Immunization Information Systems: The Community Guide; [updated 27 August, 2019. Available from: https://www.thecommunityguide.org/findings/vaccination-programs-immunization-information-systems .
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–9.

Auteurs

Ryan Smith (R)

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Jeffery Hubers (J)

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Room 4240-01A MFCB, Madison, WI, 53705, USA.

Francis A Farraye (FA)

Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.

Emmanuel Sampene (E)

Department of Biostatics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA.

Mary S Hayney (MS)

University of Wisconsin School of Pharmacy, Madison, WI, USA.

Freddy Caldera (F)

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Room 4240-01A MFCB, Madison, WI, 53705, USA. fcaldera@medicine.wisc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH